Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLX-1117
- Development stage
- Preclinical
- Lead developer
- Orchid Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BLX-1117 is an amino acid-conjugated small molecule (molecular weight < 500 Da) developed as an oral anti-diabetic agent. Unlike traditional thiazolidinediones (TZDs) such as rosiglitazone, BLX-1117 does not exhibit affinity for peroxisome proliferator-activated receptor gamma (PPARγ) and does not stimulate adipogenesis in 3T3-L1 fibroblasts. In vitro studies have demonstrated that BLX-1117 is non-toxic to human liver (HepG2) cells and effectively stimulates glucose uptake in 3T3-L1 adipocytes, suggesting a novel PPARγ-independent mechanism of action for the treatment of type 2 diabetes.
Beyond the preview
Go deeper on BLX-1117.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLX-1117.